Cargando…

Androgen Deprivation Therapy and Cardiovascular Risk

Detalles Bibliográficos
Autores principales:	Mourmouris, Panagiotis, Efstathiou, Eleni, Papatsoris, Athanasios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2012
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614327/ https://www.ncbi.nlm.nih.gov/pubmed/23577326 http://dx.doi.org/10.5812/numonthly.7597

Ejemplares similares

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Effect of androgen deprivation therapy on cardiovascular risk factors in prostate cancer
por: Roayaei, Mahnaz, et al.
Publicado: (2013)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Androgen deprivation therapy and Gleason grade: unravelling implications on survival
por: Scott, Michael, et al.
Publicado: (2019)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Financial toxicity differences between chemical versus surgical androgen deprivation therapy
por: Aragon-Ching, Jeanny B., et al.
Publicado: (2022)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE
por: Gong, Jun, et al.
Publicado: (2022)

Androgen-Deprivation Therapy and Cardiovascular Disease Risk – The Role of Exercise in Prostate Cancer Treatment
por: Wall, Bradley
Publicado: (2016)

Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
por: Fradin, James, et al.
Publicado: (2023)

Effects of androgen deprivation therapy duration and Gleason grade on survival outcomes of high risk prostate cancer
por: Kim, Do Kyung, et al.
Publicado: (2019)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Novel Optical Technology in Bladder Cancer Diagnosis and Treatment
por: Dellis, Athanasios, et al.
Publicado: (2014)

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation‐based therapy
por: Turco, Fabio, et al.
Publicado: (2022)

Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2021)

Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
por: Kim, Janice, et al.
Publicado: (2023)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Sternberg, Cora N
Publicado: (2016)

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer
por: Shastri, Bhavin R., et al.
Publicado: (2011)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

Safety first: evidence for delay of radical prostatectomy without use of androgen deprivation therapy during COVID-19
por: Sean Ong, Xuan Rui, et al.
Publicado: (2020)

AB125. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2015)

AB187. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality
por: Niu, Yuanjie, et al.
Publicado: (2016)

Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review
por: Kakarla, Meghana, et al.
Publicado: (2022)

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study
por: Haque, Reina, et al.
Publicado: (2017)

Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
por: Essien, Okon Ekwere, et al.
Publicado: (2016)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Duration of Androgen Deprivation Therapy and Cardiovascular Fitness: Delivering the Right Patient the Right Therapy at the Right Time
por: Narayan, Vivek, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
por: Wu, Szu-Yuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fpmgcbbh9n7u66n85jvrp5ab15